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Reperfusion of ischemic cardiac tissue is the standard treatment for improving
clinical outcome following myocardial infarction but is inevitably associated with
ischemia-reperfusion injury (IRI). Ischemic myocardial injury can be alleviated by exposing
the heart to brief episodes of sublethal ischemia-reperfusion prior to the ischemic insult,
a phenomenon that has been termed ischemic preconditioning (IPC). Similarly, remote
IPC (RIPC) is defined as transient episodes of ischemia at a distant site before a
subsequent prolonged injury of the target organ. In this setting, adaptive responses to
hypoxia/ischemia in peripheral tissues include the release of soluble factors that have
the potential to protect cardiomyocytes remotely. Oxygen fluctuations is a hallmark of
insufficient tissue perfusion and ischemic episodes. Emerging evidence indicates that
prolyl hydroxylase oxygen sensors (PHDs) and hypoxia-inducible transcription factors
(HIFs) are critical regulators of IPC and RIPC. In this review, we discuss recent findings
concerning the role of the PHD-HIF axis in IPC and RIPC-mediated cardioprotection and
examine molecular pathways and cell types that might be involved. We also appraise the
therapeutic value of targeting the PHD-HIF axis to enhance cardiac tolerance against IRI.
Keywords: ischemic preconditioning, heart, PHD oxygen sensors, hypoxia-inducible factors, remote ischemic
preconditioning
Ischemia-Reperfusion Injury
Ischemic heart disease represents a heterogeneous group of pathological conditions characterized
by insufficient perfusion of the heart. Coronary artery revascularization and reperfusion of
ischemic cardiac tissue is the standard treatment in patients with myocardial infarction. However,
reperfusion by itself causes additional tissue injury (termed ischemia-reperfusion injury, IRI) and
is associated with a burst of reactive oxygen species (ROS) production and intracellular calcium
overload (Garcia-Dorado et al., 1992; Kevin et al., 2003; Piper et al., 2006; Murphy and Steenbergen,
2008). Mitochondrial dysfunction plays a central role in cardiomyocyte damage during reperfusion
injury (RI). The mitochondrial inner membrane is impermeable to most metabolites and ions;
however, in certain stress conditions that can take place during IRI, such as increased calcium
concentration, metabolic failure, or oxidative stress, the non-specific mitochondrial permeability
transition pore (mPTP) opens in the inner mitochondrial membrane leading to cell death
(Halestrap et al., 2004). IRI can be limited to some extent by subjecting the heart to short sublethal
cycles of ischemia-reperfusion (ischemic preconditioning, IPC) prior to a harmful ischemic insult.
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Cardiac protection can also be induced by subjecting non-
cardiac tissues (e.g., skeletal muscle) to a transient ischemic
challenge (remote ischemic preconditioning, RIPC), resulting
in the release of cardioprotective soluble factors by the remote
ischemic tissue (Murry et al., 1986; Kharbanda et al., 2002).
Given the relevance of oxygen fluctuations during sublethal
and lethal ischemia-reperfusion cycles, the molecular pathways
driven by the oxygen sensors prolyl hydroxylases (PHDs) and
the hypoxia-inducible factors (HIFs) are extensively involved in
the mechanisms underlying IPC (Figure 1). Moreover, emerging
evidence suggests that activation of the PHD-HIF axis in RIPC
leads to secretion of HIF-dependent cytoprotectors in peripheral
tissues (e.g., skeletal muscle) that could ultimately protect the
myocardium from IRI remotely (Figure 1). Here we review
recent advances and perspectives on the role of these PHD-HIF
oxygen-sensing pathways in cardioprotection during IPC and
RIPC.
The PHD-HIF Oxygen-Sensing Pathway
The hypoxia-inducible transcription factors (HIF-1α, -2α, -3α)
and the oxygen sensors (PHD 1, 2, 3, and factor inhibiting
FIGURE 1 | Cardioprotection through the PHD-HIF pathway. Cardiac
tolerance against IRI (ischemia reperfusion injury) can be initiated by HIF1α
activation locally in the cardiac tissue during IPC (ischemia
preconditioning). IPC in the heart leads to cardiac PHD inhibition and
subsequent induction of a HIF1α-dependent cardiac metabolic
reprogramming, vessel remodeling and activation of the RISK pathway,
which ultimately results in reduced cardiac oxidative stress, prevention of
mitochondrial permeability transition pore (mPTP) opening and cardiac
tissue salvage. The potential role of alternative PHD targets in IPC is
indicated. Cardiac tolerance against IRI can be initiated by HIF1α
activation at distance in non-cardiac tissue (i.e., hind limb) during RIPC
(remote ischemia preconditioning). This remote HIF1α activation releases
HIF-dependent soluble cardioprotectors (i.e., IL-10) from the remote tissue
into the blood stream. These soluble factors initiate heart protection by
activation of RISK pathways to confer cardiac tolerance against IRI,
although additionally metabolic reprogramming and vessel remodeling
could be potentially involved. The putative role of alternative
PHD-dependent targets involved in RIPC is indicated.
HIF, FIH) are key players in the cellular response to hypoxia.
Insufficient oxygen supply to tissues rapidly increases the protein
levels of HIFα subunits, which heterodimerize with their HIFß
partner to activate transcription of a large number of target
genes involved in the adaptive cellular and systemic response to
oxygen deprivation (Semenza, 2007). HIFα subunits, however,
do not sense oxygen directly. A family of oxygen-dependent
2-oxoglutarate dioxygenases that includes PHDs and factor
inhibiting HIF (FIH) performs this activity. PHDs and FIH
modulate HIF stabilization and transcriptional activation by
hydroxylating specific prolyl or asparaginyl residues of HIFα
subunits, respectively (Schofield and Ratcliffe, 2004). Under
normal oxygen tensions, the hydroxylated prolyl residues of
HIFα subunits serve as molecular marks for von Hippel-Lindau
(VHL) protein, the recognition subunit of an E3 ubiquitin ligase
complex, which labels HIFα subunits, through ubiquitination, for
subsequent proteasomal degradation (Safran and Kaelin, 2003;
Schofield and Ratcliffe, 2004). Under hypoxia, PHDs and FIH
become inactive, resulting in stabilization of HIFα subunits.
HIFα subunits then dimerizes with HIFß and translocates to the
nucleus to recruit the transcriptional coactivator p300, which is
essential for the transcriptional activity of HIFα (Lando et al.,
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2003). As numerous pathological conditions are associated with
changes in oxygen tensions, there is a growing interest in
understanding the role of the PHD-HIF axis in clinical settings,
especially regarding its relevance in IPC- and RIPC-mediated
cardioprotection.
Cardiac PHD-HIF Oxygen-Sensing
Pathways in IPC
IPC is an effective strategy to protect the heart from IRI. This
approach requires one or more short sublethal cycles of IR by
coronary occlusion to protect the heart against a subsequent
longer period of ischemia followed by reperfusion. Emerging
evidence suggests that this phenomenon is mediated by the PHD-
HIF oxygen-sensing pathway and has been reviewed elsewhere
in detail (Fraisl et al., 2009). Thus, cardiac upregulation of
HIF-1α occurs during IPC (Eckle et al., 2008), and partial
deficiency or silencing of HIF-1α causes complete loss of IPC-
induced protection against myocardial ischemia (Cai et al., 2008).
Conversely, genetic inactivation or pharmacological inhibition of
PHDs, leading to HIF-1α activation, confers cardiac tolerance to
IRI (Eckle et al., 2007, 2008; Hyvarinen et al., 2010; Holscher
et al., 2011; Ong et al., 2014b). Below, we discuss some of the
HIF-dependent molecular responses that could be involved in
this cardioprotective effect (Figure 1).
Reprogramming of Cardiac Metabolism
Under conditions of limiting oxygen, cells reprogram their
energy demands by promoting anaerobic metabolism. This
response is mediated by HIF-dependent induction of glycolytic
enzymes and also genes involved in the attenuation of oxidative
metabolism such as pyruvate dehydrogenase kinases (PDK) -1,
-3, and -4 (Semenza et al., 1994; Kim et al., 2006; Papandreou
et al., 2006; Lu et al., 2008; Zhong et al., 2010), NDUFA4L2
(Tello et al., 2011), and the microRNA-210 (miR210) (Chan
et al., 2009; Chen et al., 2010). Since reperfusion of ischemic
tissues can lead to the formation of toxic ROS, triggering cell
death, it has been proposed that HIF-dependent reduction of
mitochondrial activity might help to counteract cell damage
by attenuating the generation of mitochondrial ROS. Along
this line, mice deficient for PHD1 present striking resistance to
low flow hindlimb ischemia and liver IRI mimicking an IPC
scenario (Aragones et al., 2008; Schneider et al., 2010). Protection
seems to be associated with energetic reprogramming toward
anaerobic metabolism, ultimately reducing mitochondrial
oxygen consumption (Aragones et al., 2008; Schneider et al.,
2010). Recent studies suggest that this anaerobicmetabolic switch
induced by PHDs could be relevant in cardiac IPC. Indeed, it has
been observed that hearts from a PHD2 hypomorphic mouse
(PHD2gt/gt), with partial reduction of PHD2, display a modest
stabilization of HIF factors and a subsequent increase in some,
but not all, metabolic genes previously identified as HIF-1α target
genes (Hyvarinen et al., 2010). Accordingly, the expression of the
glucose transporter-1 (Glut-1), phosphofructokinase-1 (Pfk-l),
triosephosphate isomerase (Tpi), phosphoglycerate kinase-1
(Pgk-1) and Pdk-1 genes is specifically increased, indicating
that these metabolic players could be particularly sensitive
to modest elevations of HIF in PHD2gt/gt heart. In line with
this transcriptional program, pre-ischemic hearts of PHD2gt/gt
hypomorphic mice show enhanced lactate secretion as well as a
mild mitochondrial swelling that does not compromise cardiac
function. Importantly, when subjected to IR using an ex vivo
Langendorff perfusion protocol, hearts from PHD2gt/gt mice
exhibit improved recovery of cardiac function and an increased
amount of ATP (Hyvarinen et al., 2010), suggesting that their
particular cardiac metabolic adaptation could be responsible for
IRI tolerance. Moreover, additional studies in which PHD2 was
either inactivated globally (Minamishima et al., 2008), or in a
cardiomyocyte-restricted manner (Holscher et al., 2011), have
also demonstrated submaximal HIF activation accompanied
with a mild mitochondrial swelling (Minamishima et al., 2008)
together with increased expression of Glut1, Pgk, Pfkl and Pdk1
genes and protection against myocardial infarction (Holscher
et al., 2011). A recent study has addressed whether this metabolic
reprogramming could be directly involved in HIF-dependent
cardiac tolerance to IRI (Ong et al., 2014b). Accordingly,
mice treated with the PHD inhibitor GSK360A have elevated
cardiac expression of the glycolytic enzyme hexokinase II, which
translocates to mitochondria to alleviate oxidative stress and
inhibit mPTP opening (Ong et al., 2014b). Taken together, these
findings suggest that an increased cardiac glycolytic rate upon
heart activation of HIF could represent, by itself, a promising
cardioprotector mechanism. Nonetheless, it is important to
note that a more robust activation of HIF by vhl gene deletion
(Lei et al., 2008) or simultaneous inactivation of PHD2 and
PHD3 (Minamishima et al., 2008, 2009; Holscher et al., 2011)
leads to a more marked repression of cardiac mitochondrial
content, which although undoubtedly prevents the formation
of deleterious mitochondrial ROS, also leads to the inevitable
impairment of cardiac function (Lei et al., 2008; Minamishima
et al., 2009). Moreover, chronic activation of the HIF-1α/PPARγ
axis may contribute to cardiac hypertrophy and heart failure
progression by promoting the switch from fatty acid utilization
to glycolysis and subsequent lipid accumulation in the heart
(Krishnan et al., 2009). Globally, these studies suggest that to
confer cardioprotection, activation of the PHD-HIF pathway
and subsequent metabolic reprogramming in the heart cannot
exceed a certain level as disproportionate HIF-activation can lead
to heart damage, cardiomegaly and impaired cardiac function
(Lei et al., 2008; Minamishima et al., 2008, 2009; Holscher et al.,
2011).
Cardiac Endothelial/Vascular Remodeling
Cardiomyocyte-specific PHD2-deficientmice present an increase
in heart capillary density, which may positively contribute to
cardioprotection after myocardial infarction (Holscher et al.,
2011). Comparable findings are found in other mouse models
associated with stronger cardiac HIF activation (Takeda et al.,
2007; Lei et al., 2008; Minamishima et al., 2009; Holscher
et al., 2011). Notwithstanding the intrinsic cardiac tolerance
of PHD2gt/gt mice to reperfusion described in the Langendorff
model, endothelial cells have also been suggested to participate in
the in vivo cardioprotection in these mice upon IRI (Hyvarinen
et al., 2010). Expression of PHD2mRNA in PHD2gt/gt transgenic
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mice is reduced by 76% in cardiac endothelial cells, 77% in
cardiac fibroblasts and almost 93% in cardiomyocytes, leading
to cardiac stabilization of HIF-1α and HIF-2 α (Kerkela et al.,
2013). These mice present an overall improved cardiac function
measured as an increase in left ventricular (LV) ejection
fraction after a 30-min cycle of ischemia by ligation of the left
anterior descending (LAD) coronary artery followed by 24 h
of reperfusion. Despite the similar capillary density in wild
type and PHD2gt/gt mice, the size of the coronary vessels is
significantly enlarged and dilated in the transgenic mice, which
might be associated with the significantly larger area of the
LV perfused during ligation (Kerkela et al., 2013). Regarding
the potential molecular mechanisms involved in the remodeling
of vessels, inhibition of PHD2 in the heart correlates with
increased expression of the endothelial genes angiopoietin-2
(Ang2), the angiopoietin receptor Tie-2, Apelin and Apelin
receptor, and blockade of Tie2 signaling impairs vessel dilation
and greatly abrogates cardiac protection after IRI. Nevertheless,
in this study, the AR/LV (area at risk/left ventricle) ratio was
not completely reversed in transgenic mice when Tie2 signaling
was inhibited, resulting in increased vascular perfusion. Thus,
additional vasodilator factors, such as nitric oxide (NO), may
participate in the vascular phenotype and cardiac protection of
these mice (Kerkela et al., 2013).
The Reperfusion Injury Signaling Kinase (RISK)
Pathway
The RISK pathway comprises a group of pro-survival protein
kinases (including Akt and Erk1/2) activated by receptor-
dependent and-independent mechanisms, which attenuate
mPTP opening and promote cardioprotection during the
reperfusion stage of IR (Tsang et al., 2004; Park et al., 2006;
Hausenloy and Yellon, 2007). Several studies have identified
molecular links between HIF activity and the RISK pathway.
Thus, PHD2-deficient hearts, or wild-type hearts subjected
to IPC, upregulate key molecules of the adenosine signaling
pathway, which are described to promote cardioprotection
through the RISK pathway (Hausenloy and Yellon, 2007).
Some adenosine signaling molecules include the A2B adenosine
receptor (A2BAR) and the ecto-5′-nucleotidase CD73, which
generates adenosine. Interestingly, CD73 expression is not
activated in PHD2gt/gt hypomorphic mice (Hyvarinen et al.,
2010), suggesting that in this background cardioprotection might
be obtained through adenosine-independent signaling, such as
for instance the metabolic reprogramming mentioned above.
Therefore, it would be pertinent to explore whether additional
elements of the RISK pathway are activated in PHD2gt/gt mice,
or whether RISK activation requires a stronger cardiac HIF
induction. An additional mediator of cardioprotection could be
erythropoietin (Epo), the archetype HIF-responsive gene, which
we recently found elevated in vhl-deficient hearts (Miro-Murillo
et al., 2011). Indeed, several reports have shown that Epo
protects cardiac tissue during ischemia and IR, particularly by
overactivating the serine threonine kinase Akt, as well as through
other pathways involving sonic hedgehog (Camici et al., 2007;
Burger et al., 2009; Ueda et al., 2010; Ong et al., 2014a). Thus,
it is conceivable that cardiac Epo expression could serve as a
local autocrine or paracrine cardioprotector during IPC. In
addition, several studies have also shown that cardiac HIF-1α
expression can increase sublethal ROS production, resulting
in oxidation/inactivation of the protein/lipid phosphatase
and tensin homolog (PTEN), which negatively regulates the
PI3K/Akt survival pathway (Cai and Semenza, 2005; Mocanu
and Yellon, 2007; Cai et al., 2008). Therefore, HIF-1α could
overactivate the prosurvival signaling cascades of Akt not only
through extracellular soluble factors (e.g., adenosine and Epo),
but also by ROS-mediated PTEN inactivation. The mechanisms
by which Akt attenuates mPTP opening are still not completely
understood, though recent studies suggest that Akt-dependent
changes in mitochondrial morphology are required for
Akt-dependent cardioprotection against IRI (Ong et al., 2014a,b).
Nitric Oxide Signaling
Cardiac IPC upregulates the HIF-dependent gene inducible
nitric oxide synthase (iNOS) and, importantly, iNOS
deficiency abrogates the late phase of IPC (Guo et al., 1999).
Increased intracellular nitric oxide (NO) as a consequence of
endothelial/inducible NOS (eNOS)/iNOS activation plays a
central role in cardiac IPC (Jones et al., 1999; Jung et al., 2000;
Divisova et al., 2001; Vavrínková et al., 2001; Gao et al., 2002;
Murphy and Steenbergen, 2008). At the molecular level, NO-
dependent cardioprotection involves stimulation of guanylyl
cyclase, which leads to cGMP production and subsequent
activation of protein kinase G (PKG). Activated PKG in turn
activates mitochondrial pKCε-dependent opening of mito-KATP
channels (Costa et al., 2005), resulting in K+ influx, matrix
alkalinization and subsequent ROS generation (Yao et al., 1999;
Andrukhiv et al., 2006; Costa et al., 2008). Regarding the source
of ROS, studies in isolated rat mitochondria have shown that
intramitochondrial ROS generation is driven by complex I of the
electron transport chain (Andrukhiv et al., 2006) and an earlier
study using intact embryonic chick cardiomyocytes suggested
the participation of complex III (Yao et al., 1999). Regardless
of the mechanisms involved in their generation, mito-KATP
channel-dependent sublethal ROS production is implicated in
cardioprotection (Yao et al., 1999; Forbes et al., 2001; Gross and
Lockwood, 2004; Shahid et al., 2008) because of their ability to
activate an additional PKCε pool which ultimately inhibits mPTP
opening (Costa et al., 2008). Thus, it is possible that PKG and
iNOS constitute the molecular link between HIF and sublethal
ROS-mediated PTEN inactivation and Akt activation. In fact,
iNOS is phosphorylated and activated by Akt, and therefore
the iNOS-NO-PKG molecular axis has been positioned as a
downstream effector of Akt in IPC (Hausenloy et al., 2005). Also,
local cardiac NO release may influence vascular tone and thus
impact cardiac perfusion upon IRI (Fraisl, 2013).
PHD-HIF Oxygen Sensing Pathways in
RIPC
HIF-Dependent Soluble Factors in RIPC
In addition to the phenomenon of IPC described earlier,
recent observations indicate that transient and local exposure
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to hypoxia in certain tissues (limb skeletal muscle, brain,
intestine, and kidney) are protective against future ischemic
insults to organs and tissues distant from the regional area
of initial ischemia, with similar efficacy as local IPC. This
unique and innovative treatment approach has been named
remote ischemic preconditioning or RIPC (Bolte et al., 2007;
Randhawa and Jaggi, 2014). The potential clinical applications
of this endogenous adaptive capacity are enormous and are
especially attractive in the setting of clinical interventions to
resolve highly prevalent cardiovascular diseases such as coronary
obstruction, heart failure or stroke, where tissue reperfusion
after an ischemic insult could have devastating consequences
(Bolte et al., 2007; Randhawa and Jaggi, 2014). As a simple,
inexpensive and relatively uncomplicated approach to reduce
cardiovascular perioperative ischemic damage, there is a growing
interest in understanding the molecular mediators (i.e., soluble
factors) involved in ischemic protection to improve and develop
novel therapeutic strategies. Results from preclinical studies
have shown that transient occlusion of cerebral, mesenteric or
intestinal arteries, as well as the abdominal aorta or skeletal
muscle, promotes cardioprotection against IRI by myocardial
preconditioning (Randhawa and Jaggi, 2014). In spite of the
clinical benefits reported to the date, identification of the
protective factors involved in RIPC and how they impact on
myocardial survival upon reperfusion remains largely unknown;
nevertheless, some novel soluble factors have emerged in the
setting of RIPC and recent studies point to a role for the PHD-
HIF pathway in RIPC (Figure 1). Stabilization of HIF-1α protein
in the heart after remote ischemic injury has been confirmed both
in basic models (Cai et al., 2013; Kalakech et al., 2013) and also in
human clinical trials (Albrecht et al., 2013; Randhawa and Jaggi,
2014). The possibility that HIF-1 could control the expression of
soluble factors to promote cardioprotection in RIPC was initially
tested in muscle tissue using gene delivery of HIF-1 (Czibik
et al., 2009). Additionally, a positive role for HIF-1 was suggested
by experiments showing that HIF-1α-deficient mice completely
lose RIPC-induced cardioprotection after transient ligation of the
femoral artery (Cai et al., 2013). Using a similar experimental
approach based on heterozygous HIF-1α heterozygous mice
and pharmacological inhibition of HIF with cadmium, Kalakech
and colleagues reported that HIF-1 was unnecessary in acute
RIPC (Kalakech et al., 2013). A potential explanation for
these discrepancies could be the subtle technical differences in
the hindlimb ischemia protocol to induce RIPC, infarct size
determination or the time between the transient ligation of the
femoral artery and coronary occlusion. Moreover, despite the
dramatic reduction of HIF-1α protein in the limbs of HIF-1α
heterozygous mice after RIPC or cadmium treatment, HIF-1α
levels were above the control condition. Because all or part of the
effects mediated by the secreted component of the RIPC response
may be dose dependent, it cannot be ruled out that this minimum
amount of HIF-1 may be enough to activate the paracrine-
protective mechanism in response to myocardial infarction.
Regarding the HIF-dependent soluble factors that could mediate
RIPC, Cai and colleagues showed that interleukin-10 (IL-10) is
a primary HIF-1α target in murine cardiomyocytes subjected
to cyclic hypoxia-reoxygenation. Furthermore, transient femoral
ligation increases IL-10 plasma concentration and promotes a
subsequent remote activation of cardiac Akt signaling. This effect
is inhibited in HIF-1α heterozygous deficient mice, suggesting
that IL-10 could be responsible for the activation of Akt pathway
in the distant heart and subsequent cardioprotection (Cai et al.,
2013). In line with the characterization of mechanisms mediating
cardioprotection by IL-10, it has been reported that this cytokine
can prevent hypertrophic remodeling and improve cardiac
function in a model of isoproterenol-induced pressure overload
by controling Stat-3 activation and promoting NFκB inhibition
(Verma et al., 2012). In addition, the group of Pawan K. Singal
has shown that IL-10 promotes Stat-3 activation associated
with Akt phosphorylation in cardiomyocytes (Dhingra et al.,
2011). Furthermore, when IL-10-stimulated cardiomyocytes are
treated with the ERK1/2 MAPK inhibitor PD 98059, the
cardioprotection mediated by this anti-inflammatory cytokine is
lost (Dhingra et al., 2009). Also, a recent study has shown that
IL-10 activates Toll-like receptor 4 and mediates cardiomyocyte
survival in a MyD88-interferon regulatory factor 3 (IRF3)-NFκB
dependent manner (Bagchi et al., 2013). However, it is important
to consider the potential roles of additional HIF-dependent genes
in RIPC. Accordingly, hindlimb ischemia also elevates in plasma
the stromal cell-derived factor 1 (SDF-1) also known as C-X-C
motif chemokine 12 (CXCL12), which mediates cardioprotection
through its receptor CXCR4 (Davidson et al., 2013). Indeed, this
study demonstrated that AMD3100, a highly specific inhibitor
of CXCR4, blocked RIPC upon transient femoral ligation,
suggesting that IL-10 and SDF1 could act in concert to confer
HIF-dependent cardioprotection at a distance.
Finally, cardioprotection after RIPC could be mediated
by additional HIF-1α–independent signaling involving soluble
factors, such as HIF-2α stabilization and subsequent Epo
production (Kapitsinou et al., 2014) or NFκB signaling (Kant
et al., 2008). Along this line, one of the original signals described
in IRI models, mito-KATP channel opening, was found to be
a downstream mediator of NFκB activation in a rat model of
renal RIPC, with positive effects for cardioprotection (Diwan
et al., 2008). In terms of pharmacological HIF-PHD inhibition
strategies in the setting of RIPC, it is important to appreciate
that NFκB signaling is targeted and activated upon PHD
inhibition (Cummins et al., 2006), potentially contributing to the
secretion of inflammatory mediators that might be critical in the
evolution of the ischemic insult upon RIPC. Nonetheless, the
relative contribution of PHD-dependent but HIF-1-independent
pathways in cardiac protection remains poorly explored and
warrants further investigation.
Cardiac Cell Types Potentially Involved in RIPC
In addition to cardiomycoytes, the heart is a complex structure
composed of many cell types. In the setting of RIPC initiated
by extracellular soluble factors, aside from cardiomyocytes, other
heart cell types might also respond to cytoprotectors to mediate
global cardiac protection. As discussed earlier, the vascular
endothelium is an essential element mediating IPC salvage and,
in the setting of RIPC, it might also be prudent to determine
if some or any of the described cardiac secreted factors (IL-
10, SDF1, Epo, etc.) could directly impact endothelial cells to
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mediate heart protection by regulating the coronary diameter,
endothelial permeability or vascular tone. In this respect, the
presence of Epo receptors on endothelial cells and the activation
of the PI3K/Akt pathway in response to Epo have been previously
evaluated (Marzo et al., 2008). Additionally, IL-10 has been
described to protect against aging or inflammation-mediated
endothelial dysfunction (Kinzenbaw et al., 2013) and SDF1 has
been reported to increase capillary density in a murine model
of myocardial infarction (Ziegler et al., 2012). Another heart
component potentially mediating cardioprotection upon RIPC is
the epicardium, the outer most layer of the heart that, during
development, contributes to the formation of the coronary
vasculature and interstitial cardiac fibroblasts (Martin-Puig
et al., 2008). Interestingly, upon myocardial infarction, murine
epicardial-derived cells (EPDCs) secrete a plethora of paracrine
factors mostly related to angiogenesis (Vegfa, Angpt1, Ang, Fgf1,
Fgf2, Fgf9, Pdgfa, Pdgfc, Pdgf) among others (Adamts1, Sdf1,
Mcp1, and IL-6) and are able to proliferate and migrate toward
the infarcted myocardium, giving rise to perivascular fibroblasts
and smooth muscle cells (Zhou et al., 2011). Remarkably, this
paracrine response is associated with a reduction of infarct
size and improvement in cardiac function (Zhou et al., 2011).
Since some of these secreted molecules are HIF targets and
others, for instance SDF1, have previously been described
as beneficial factors produced upon RIPC, EPDCs could
reasonably be mediating part of the cardiac protection provided
by RIPC.
Finally, the involvement of soluble mediators such as active
cytokines in the cardioprotective effect of RIPC, points to the
potential modulation of different aspects of the immune system
that could contribute to their beneficial effects. Thus, it will be
of special interest to identify the cytokine signature upon RIPC
that could modulate immune cell phenotypes such as M1/M2
macrophages and Th17/Treg lymphocyte polarization. Indeed,
the participation of NFκB signaling in RIPC cardioprotection
(Diwan et al., 2008; Kant et al., 2008) offers a potential interplay
between RIPC, the PHD-HIF pathway and modulation of the
immune system.
Concluding Remarks and Therapeutic
Opportunities
Emerging evidence suggests that the PHD-HIF oxygen-sensing
pathway induces cardiac intracellular responses (metabolic
reprogramming) as well as systemic protective mechanisms
initiated by extracellular factors (adenosine, Epo, NO, etc.),
which contribute to myocardium salvage during reperfusion.
The extracellular component of cardioprotection is strongly
supported by the benefits of RIPC that rely on soluble factors
released by peripheral ischemic tissues (e.g., IL-10 and SDF1),
which subsequently activate cardioprotective RISK pathways in
cardiac tissue (Figure 1). Thus, in the setting of IPC or RIPC,
it might be important firstly to identify novel HIF-dependent
soluble cardioprotectors and, secondly, to investigate the impact
of these extracellular factors on the coronary endothelium
regulating tissue perfusion, or through additional mechanisms,
to promote cardioprotection. Importantly, pharmacological
inhibition or genetic inactivation of PHD oxygen sensors
has been shown to confer ischemic tolerance in heart tissue,
which could have clinical impact in countering IR damage.
Notwithstanding the potential cardioprotection offered by global
HIF activation after systemic PHD pharmacological inhibition,
some deleterious side effects may occur when cardiac HIFs are
overactivated such as reduced cardiac mitochondrial function
or lipid accumulation in the heart. An alternative therapeutic
opportunity might be focused on local chemical inhibition of
PHDs in remote tissues (e.g., skeletal muscle) in an attempt
to mimic the endogenous RIPC response. A caveat to these
approaches, however, is that a HIF-dependent cardioprotective
program requires some time (perhaps hours), which could limit
to some extent its clinical value when the ischemia/reperfusion
episode is taking place. A more specific approach could
exploit HIF-dependent soluble/secreted factors involved in IPC
(adenosine) or RIPC (IL-10, SDF1) as therapies. Indeed, alone
or in combination, these factors could be administered in the
reperfused cardiac tissue when the occluded coronary artery
is reopened. Along this line, the administration of some HIF-
dependent soluble factors, such as adenosine or Epo, have been
clinically tested in humans although the clinical efficacy has not
been fully addressed (Singh et al., 2012; Mastromarino et al.,
2013; Talan and Latini, 2013; Garcia-Dorado et al., 2014; Lund
et al., 2014) and further research needs to be conducted in terms
of posology and time of administation. A better understanding
of the molecular mechanisms linking HIF-secreted factors to
cardioprotection and the identification of novel HIF-dependent
extracellular molecules will help to overcome these limitations
and improve clinical benefits toward salvage of ischemic
myocardium.
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